Literature DB >> 15085421

The co-existence of Fabry and celiac diseases: a case report.

Leyla Tümer1, Fatih S Ezgü, Alev Hasanoğlu, Buket Dalgiç, Sevcan A Bakkaloğlu, Leyla Memiş, Ayşe Dursun.   

Abstract

We present a patient with Fabry disease with remarkable diagnostic findings and gluten-sensitive enteropathy. An 11-year-old girl was admitted to hospital with weight loss, anorexia, nausea, vomiting, flank pain, acroparesthesia, and painful extremities. Her mother had end-stage renal failure secondary to Fabry disease. On physical examination, she had growth retardation. Ophthalmological examination showed characteristic whorl-like corneal opacities and Fabry disease was confirmed with low alpha-galactosidase A (alpha-gal A) activity. Her painful attacks were treated with carbamazepine, but vomiting and nausea continued. Laboratory studies revealed positive serum anti-endomysium and anti-gliadin antibodies. Small intestinal biopsy showed subtotal villous atrophy compatible with gluten-sensitive enteropathy. Following treatment with a gluten-free diet, her gastrointestinal symptoms completely disappeared within a few weeks and then she had catch-up growth. In her long-term follow-up, proteinuria appeared and renal involvement was confirmed by characteristic renal biopsy findings. Following these clinicopathological findings, enzyme replacement therapy was started. In conclusion, although heterozygous females can be asymptomatic or are expected to have a mild course of the disease, a severe clinical course in our patient in the 2nd decade is of particular interest. In addition, Fabry disease occurring with gluten-sensitive enteropathy, a very rare co-existence, is emphasized.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15085421     DOI: 10.1007/s00467-004-1462-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  10 in total

1.  Anderson-Fabry's disease: alpha-galactosidase deficiency.

Authors:  F P Peters; A Vermeulen; T L Kho
Journal:  Lancet       Date:  2001-01-13       Impact factor: 79.321

Review 2.  Enzyme replacement therapy for Fabry disease: proving the clinical benefit.

Authors:  Frank Breunig; Christoph Wanner
Journal:  Nephrol Dial Transplant       Date:  2003-01       Impact factor: 5.992

Review 3.  Natural history and treatment of renal involvement in Fabry disease.

Authors:  Mary Branton; Raphael Schiffmann; Jeffrey B Kopp
Journal:  J Am Soc Nephrol       Date:  2002-06       Impact factor: 10.121

4.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

5.  Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes.

Authors:  C Whybra; C Kampmann; I Willers; J Davies; B Winchester; J Kriegsmann; K Brühl; A Gal; S Bunge; M Beck
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

Review 6.  X-chromosome inactivation: a repeat hypothesis.

Authors:  M F Lyon
Journal:  Cytogenet Cell Genet       Date:  1998

7.  Letter: Occurrence of celiac sprue in a patient with Fabry's disease.

Authors:  C H Halsted; J W Rowe
Journal:  Ann Intern Med       Date:  1975-10       Impact factor: 25.391

8.  Gastrointestinal structure and function in Fabry's disease.

Authors:  K J Sheth; S L Werlin; M E Freeman; A E Hodach
Journal:  Am J Gastroenterol       Date:  1981-09       Impact factor: 10.864

9.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

10.  Different phenotypic expression in relatives with fabry disease caused by a W226X mutation.

Authors:  I E Knol; M G Ausems; D Lindhout; O P van Diggelen; H Verwey; J Davies; J K Ploos van Amstel; B T Poll-The
Journal:  Am J Med Genet       Date:  1999-02-19
  10 in total
  7 in total

1.  Exocrine pancreatic insufficiency is not a cause of abdominal complaints in patients with Fabry disease.

Authors:  Miroslav Vujasinovic; Bojan Tepes; Bojan Vujkovac; Andreja Cokan Vujkovac; Martin Tretjak; Vesna Korat
Journal:  Wien Klin Wochenschr       Date:  2015-04-03       Impact factor: 1.704

Review 2.  Macrophage-related diseases of the gut: a pathologist's perspective.

Authors:  Xavier Sagaert; Thomas Tousseyn; Gert De Hertogh; Karel Geboes
Journal:  Virchows Arch       Date:  2012-05-11       Impact factor: 4.064

3.  IgA nephropathy in two adolescent sisters heterozygous for Fabry disease.

Authors:  Catharina Whybra; Andreas Schwarting; Jörg Kriegsmann; Andreas Gal; Eugen Mengel; Christoph Kampmann; Frank Baehner; Ellen Schaefer; Michael Beck
Journal:  Pediatr Nephrol       Date:  2006-07-13       Impact factor: 3.714

Review 4.  Recommendations for the diagnosis and management of Fabry disease in pediatric patients: a document from the Rare Diseases Committee of the Brazilian Society of Nephrology (Comdora-SBN).

Authors:  Maria Helena Vaisbich; Luís Gustavo Modelli de Andrade; Cassiano Augusto Braga Silva; Fellype de Carvalho Barreto
Journal:  J Bras Nefrol       Date:  2022 Apr-Jun

Review 5.  Pain management strategies for neuropathic pain in Fabry disease--a systematic review.

Authors:  Y Schuller; G E Linthorst; C E M Hollak; I N Van Schaik; M Biegstraaten
Journal:  BMC Neurol       Date:  2016-02-24       Impact factor: 2.474

Review 6.  Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective.

Authors:  Fatih Ezgu; Erkan Alpsoy; Zerrin Bicik Bahcebasi; Ozgur Kasapcopur; Melis Palamar; Huseyin Onay; Binnaz Handan Ozdemir; Mehmet Akif Topcuoglu; Omac Tufekcioglu
Journal:  Orphanet J Rare Dis       Date:  2022-03-02       Impact factor: 4.123

7.  The coincidence of IgA nephropathy and Fabry disease.

Authors:  Dita Maixnerová; Vladimír Tesař; Romana Ryšavá; Jana Reiterová; Helena Poupětová; Lenka Dvořáková; Lubor Goláň; Michaela Neprašová; Jana Kidorová; Miroslav Merta; Eva Honsová
Journal:  BMC Nephrol       Date:  2013-01-11       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.